AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01103830
Drug: Riamet®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets of Riamet® (20mg artemether/120mg lumefantrine) on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.
Trial: NCT06238856
Drug: SLIT™ Amikacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin administered via the Pari LC STAR™ nebulizer.
Trial: NCT06238856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized saline.
Trial: NCT03249558
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
Trial: NCT01967251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil placebo-matching tablets
Trial: NCT05943990
Drug: GSK3845097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3845097 was administered.
Trial: NCT05943990
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered as lymphodepleting chemotherapy.
Trial: NCT04193176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered twice daily as a placebo oral tablet matching gefapixant
Trial: NCT02096380
Drug: One cycle TPF induction chemotherapy for NPC
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One cycle TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2.
Trial: NCT02446990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
Trial: NCT00534586
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuous infusion 0.05 mcg/kg/min 0.15 mcg/kg/min
Trial: NCT00918398
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg iv infusion, single dose, 4 hours infusion
Trial: NCT00918398
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 514 mg oral solution, single dose
Trial: NCT00918398
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose
Trial: NCT00918398
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose
Trial: NCT03160573
Drug: ClōSYS® Unflavored Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03160573
Drug: ClōSYS® Flavored Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01829763
Drug: injection botox
RxNorm normalized name: onabotulinumtoxinA Injection [Botox]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00707369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (cellulose powder, lactose monohydrate, magnesium stearate, microcrystalline cellulose): three times daily for 7 days
Trial: NCT02016885
Drug: glycopyrrolate, 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glycopyrrolate Topical Wipes, 1.0%
Trial: NCT02016885
Drug: glycopyrrolate, 2.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glycopyrrolate Topical Wipes, 2.0%
Trial: NCT02016885
Drug: glycopyrrolate, 3.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glycopyrrolate Topical Wipes, 3.0%
Trial: NCT02016885
Drug: glycopyrrolate, 4.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glycopyrrolate Topical Wipes, 4.0%
Trial: NCT02653560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01307033
Drug: MK-0954A
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
Trial: NCT01307033
Drug: MK-954H
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily
Trial: NCT01307033
Drug: Placebo to MK-0954A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet to match MK-0954A, once daily
Trial: NCT01257893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo capsule identical in appearance and excipient to aspirin capsule per day for 10-14 consecutive days
Trial: NCT00678574
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily by mouth for 2-3 months.
Trial: NCT04187690
Drug: Jin-shui Huan-xian granule placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jin-shui Huan-xian granule placebo will also be administered 5days on and 2 days off for 52 weeks. The placebo consists 5% of the same components as Jin-shui Huan-xian granule besides dextrin and bitter. The There is no obvious difference in appearance, weight and odor between Jin-shui Huan-xian granule and placebo.
Trial: NCT01307033
Drug: Placebo to MK-954H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet to match MK-954H, once daily
Trial: NCT04551586
Drug: ACH-0145228: Immediate Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACH-0145228 (240 milligrams) will be administered orally on Day 1.
Trial: NCT04551586
Drug: ACH-0145228: Powder-in-capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACH-0145228 (240 milligrams) will be administered orally on Day 1.
Trial: NCT01507103
Drug: cyclophosphamide (CPA)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of CPA will be given 3 days before the first tecemotide (L-BLP25) administration.
Trial: NCT01140932
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 days of corticosteroids treatment (prednisolone 37,5 mg/day)
Trial: NCT01582555
Drug: saline nasal irrigation alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation
Trial: NCT03987685
Drug: Oratopo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral topotecan will be supplied in topotecan capsules and oral HM30181A-US tablets
Trial: NCT03822715
Drug: standard of care aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care aromatase inhibitors
Trial: NCT02605967
Drug: Investigator choice of chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commonly used chemotherapy as per investigator's choice. The dose and route of administration was the one described in each drug's label.
Trial: NCT01740518
Drug: polyethylene glycol, ascorbic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different solutions for bowel preparation
Trial: NCT00555087
Drug: Testosterone Undecanoate and/or PDE-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone Undecanoate 1000 mg IM injection; PDF5 tab, 20 mg
Trial: NCT04573478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT01122368
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT02662582
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT03258593
Drug: Vicineum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.
Trial: NCT03258593
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen or equivalent medications per institutional standard may be administered at the discretion of the investigator.
Trial: NCT02512237
Drug: ARX788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARX788, an antibody drug conjugate
Trial: NCT03932071
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03656614
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of saline 0.9%.
Trial: NCT01026428
Drug: Safinamide + Levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A: 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
Trial: NCT03165695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 tablet orally at 21:00 or until discharge whichever comes first
Trial: NCT01219920
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
Trial: NCT01080547
Drug: XELOX Chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XELOX chemotherapy
Trial: NCT02355509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills are given instead of acarbose in this group
Trial: NCT03484195
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 150 mg/m\^2 IV over 1h, day 1 + Oxaliplatin 85 mg/m\^2 IV over 2h, day 1 + L-Leucovorin 200 mg/m\^2 IV over 2h, day 1 + 5-Fluorouracil 2800 mg/m\^2 IV 48h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months)
Trial: NCT00069953
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During induction therapy, patients receive 650 mg/m\^2/day by IV continuously over 96 hours beginning on days 1 and 29. During radiotherapy, patients receive 300 mg/m\^2/day by IV continuously over 96 hours beginning on day 57 for 5 cycles.
Trial: NCT01219920
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
Trial: NCT00153790
Drug: PhosphoLean
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00635050
Drug: Doxil, Paclitaxel, Cyclophosphamide, Avastin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A: Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3 . Patients who experience \<pCR to primary chemotherapy will receive an additional year of Avastin 15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation.~Regimen B: Doxil 30 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3. Patients who experience \<pCR to primary chemotherapy will receive an additional year of Avastin15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation.
Trial: NCT01236456
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00104403
Drug: GW679769
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02197988
Drug: Exparel 1.33% (20ml Volume)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transversus Abdominis Plane Block
Trial: NCT02197988
Drug: 0.125% bupivicaine with 2 mcg/ml Fentanyl.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic Epidural Anesthesia
Trial: NCT01152385
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet administered twice daily during 4 months
Trial: NCT01152385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered twice daily during 4 months
Trial: NCT01475331
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cysts will be lavaged for 3-5 minutes with 80% EtOH
Trial: NCT01475331
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysts will be lavaged for 3-5 minutes with normal saline
Trial: NCT01475331
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
Trial: NCT03359395
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
Trial: NCT00100477
Drug: Mitozantrone
RxNorm normalized name: Mitozantrone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02144818
Drug: Ovitrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triggering of ovulation with Ovitrel
Trial: NCT02059642
Drug: MG01CI (1400 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily
Trial: NCT02059642
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1400 mg administered orally once daily
Trial: NCT02122185
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02122185
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will received standard chemotherapy (6-8 cycles). Specific regimen to be given is at the discretion of their treating physician.
Trial: NCT01197300
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intravenous infusion
Trial: NCT01027754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1-3: 1 pill daily Days 4-7: 2 pills daily Days 8-84: 2 pills daily
Trial: NCT04632342
Drug: HL301 tablet 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Experimental group 1 : 2 tablets at once, twice a day~* Experimental group 2 : 2 tablets at once, three times a day
Trial: NCT04632342
Drug: Placebo of HL301 tablet
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets at once, three times a day
Trial: NCT01629563
Drug: PGL4001 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGL4001 5 mg daily administration
Trial: NCT01629563
Drug: PGL4001 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGL4001 10mg daily administration
Trial: NCT00594308
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60mg/kg/day for two consecutive days (-7,-6).
Trial: NCT01480765
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days
Trial: NCT01480765
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline placebo intravenous infusion for 48 hours
Trial: NCT03735901
Drug: IMP Levodopa 100mg/Carbidopa 25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning.
Trial: NCT03735901
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning.
Trial: NCT01103830
Drug: Eurartesim™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
Trial: NCT04421664
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
Trial: NCT00001789
Drug: BG9588
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02534623
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004228
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00004228
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00004228
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00004228
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00004228
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00963885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po for 12 weeks
Trial: NCT00963885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po for 24 weeks
Trial: NCT00185614
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide administered intravenously (IV) at 4 mg /m² mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion
Trial: NCT04392362
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A vial of adenosine with 6mg
Trial: NCT01386645
Drug: high glycemic index diet plus N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
Trial: NCT04250259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months
Trial: NCT01807741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02062346
Drug: BQ123/788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: or BQ123/788 (mixed ETA/B antagonists)
Trial: NCT02062346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of saline
Trial: NCT00814736
Drug: UK369,003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, once a day
Trial: NCT04315961
Drug: Blinded drug dose conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules will contain commonly prescribed or over-the-counter drugs or placebo. Capsules in this study may contain sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, or antihistamines which must remain blinded for the purposes of this study.
Trial: NCT01548326
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one Placebo tablet orally per day for 10 days
Trial: NCT01485198
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (750mg orally TID) administration